Investigational drug · Phase 2
MK-0482
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
6
Any phase or sponsor naming "MK-0482"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-0482", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-0482" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165070 · 450 participants (planned) · Start Dec 19, 2019 · Primary completion Feb 13, 2032
Drug: Pembrolizumab; Carboplatin and 8 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 47 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03918278 · 222 participants · Start Jun 19, 2019 · Primary completion Jun 9, 2025
Drug: MK-0482; pembrolizumab and 5 more · For: Neoplasms
Sites: Detroit, Michigan; Hackensack, New Jersey; San Antonio, Texas · 16 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165096 · 128 participants · Start Jan 21, 2020 · Primary completion Apr 30, 2025
Drug: Pembrolizumab; Boserolimab and 4 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 39 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04165083 · 100 participants · Start Jan 7, 2021 · Primary completion Oct 31, 2025
Drug: Pembrolizumab; MK-4830 and 1 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Gilbert, Arizona; Duarte, California; San Francisco, California · 39 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05038800 · 13 participants · Start Sep 26, 2021 · Primary completion Dec 11, 2023
Drug: MK-0482 · For: Relapsed or Refractory Acute Myeloid Leukemia; Relapsed or Refractory Chronic Myelomonocytic Leukemia
Sites: Buffalo, New York; Houston, Texas; Jerusalem, Israel · 5 sites in all
Presage BiosciencesIndustry
NCT06413095 · 13 participants · Start Jun 1, 2022 · Primary completion Jun 22, 2023
Drug: Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma; Soft Tissue Sarcoma
Sites: Sacramento, California; Atlanta, Georgia; Shreveport, Louisiana · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.